Genetic Polymorphisms and Statin-Associated Side Effects: The Role of SLCO1B1 and Additional Risk Factors
Southeastern European Medical Journal · 23.03.2026 · 10 (1) · 15-29
DOI: 10.26332/jp55ha33 ↗Kurz gefasst
Fachartikel in der Zeitschrift Southeastern European Medical Journal, online erschienen am 23.03.2026. Verfasst von Romana Marušić und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Statins are first-line agents for managing dyslipidemia, primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease (ASCVD). Despite their proven efficacy, there is significant interindividual variability in statin response, with some patients experiencing adverse events such as statin-associated muscle symptoms (SAMS) and hepatotoxicity. These effects are partly attributable to genetic polymorphisms, particularly in the SLCO1B1 gene, which encodes the organic anion-transporting polypeptide 1B1 (OATP1B1) responsible for hepatic statin uptake. The SLCO1B1 rs4149056 polymorphism is associated with impaired transporter function, leading to elevated statin plasma concentrations and a higher risk of statin-induced myopathy, especially with simvastatin. Non-genetic factors, such as hypothyroidism, can exacerbate statin intolerance by impairing lipid metabolism and increasing the risk of myopathy and rhabdomyolysis due to reduced hepatic statin clearance. Vitamin D deficiency has also been linked to increased susceptibility to SAMS, as vitamin D plays a role in muscle function and statin metabolism through CYP enzyme modulation. Coenzyme Q10 (CoQ10) depletion, a consequence of statin therapy due to inhibition of the mevalonate pathway, may further contribute to mitochondrial dysfunction and muscle injury. Incorporating pharmacogenetic testing and addressing modifiable risk factors such as thyroid dysfunction and vitamin D deficiency may optimize statin therapy, reducing adverse effects while maintaining cardiovascular protection. Keywords: hydroxymethylglutaryl-CoA reductase inhibitors; SLCO1B1 gene; hypercholesterolemia; myopathy, statin-induced; pharmacogenomics
Zitieren
APA
Marušić, R., Bačun, T., Šojat, D., & Marczi, S. (2026). Genetic Polymorphisms and Statin-Associated Side Effects: The Role of SLCO1B1 and Additional Risk Factors. Southeastern European Medical Journal, 10(1), 15-29. https://doi.org/10.26332/jp55ha33
Vancouver
Marušić R, Bačun T, Šojat D, Marczi S. Genetic Polymorphisms and Statin-Associated Side Effects: The Role of SLCO1B1 and Additional Risk Factors. Southeastern European Medical Journal. 2026;10(1):15-29. doi:10.26332/jp55ha33
BibTeX
@article{Marui2026,
author = {Marušić, Romana and Bačun, Tatjana and Šojat, Dunja and Marczi, Saška},
title = {Genetic Polymorphisms and Statin-Associated Side Effects: The Role of SLCO1B1 and Additional Risk Factors},
journal = {Southeastern European Medical Journal},
year = {2026},
volume = {10},
number = {1},
pages = {15--29},
doi = {10.26332/jp55ha33}
}
EUVIMED